ライフサイエンスコーパス: hepatic steatosis

1 FF >/= 5% after exclusion of other causes of hepatic steatosis).

2 hat cause lipid accumulation in hepatocytes (hepatic steatosis).

3 asatinib and quercetin (D+Q) reduces overall hepatic steatosis.

4 ein B (apoB) lipoproteins but can also cause hepatic steatosis.

5 temic glucose homeostasis, inflammation, and hepatic steatosis.

6 downregulation may contribute to HCV-induced hepatic steatosis.

7 hepatic VLDL secretion that protects against hepatic steatosis.

8 xert anti-inflammatory effects and alleviate hepatic steatosis.

9 rdiac structure, energetics, and cardiac and hepatic steatosis.

10 pression of ER chaperone proteins alleviates hepatic steatosis.

11 re protected against HFD-induced obesity and hepatic steatosis.

12 es improved glucose tolerance and attenuated hepatic steatosis.

13 PPARgamma antagonists may be useful to treat hepatic steatosis.

14 obesity-associated inflammation and improve hepatic steatosis.

15 glucose intolerance, insulin resistance, and hepatic steatosis.

16 , metabolic profile, insulin resistance, and hepatic steatosis.

17 athway reversed the "Gli-code" and mitigated hepatic steatosis.

18 tissue, decreased gluconeogenesis, and less hepatic steatosis.

19 de therapeutic strategies in obesity-induced hepatic steatosis.

20 elopment of obesity, insulin resistance, and hepatic steatosis.

21 ulting in hyperglycemia, hyperlipidemia, and hepatic steatosis.

22 ulin resistance, diabetes, dyslipidemia, and hepatic steatosis.

23 or signatures of coronary artery disease and hepatic steatosis.

24 HIV patients develop hepatic steatosis.

25 d oxidation and lipolysis, and thus promoted hepatic steatosis.

26 with protection from insulin resistance and hepatic steatosis.

27 o antibiotic-treated mice fed a HFD reversed hepatic steatosis.

28 brown adipose mass; and were protected from hepatic steatosis.

29 FLD compared to BMI-matched subjects without hepatic steatosis.

30 uracy of MRI-PDFF as an imaging biomarker of hepatic steatosis.

31 by the HFD and protected against HFD-induced hepatic steatosis.

32 stologic steatosis grading for assessment of hepatic steatosis.

33 P/iDTR) mice and prevented the resolution of hepatic steatosis.

34 ic and environmental interactions underlying hepatic steatosis.

35 associated with lipodystrophy, diabetes, and hepatic steatosis.

36 mately 40-50% of obese adults do not develop hepatic steatosis.

37 relative to biopsy for the quantification of hepatic steatosis.

38 hole body fuel metabolism and a reduction in hepatic steatosis.

39 creased, and the mice were protected against hepatic steatosis.

40 een identified as a novel genetic marker for hepatic steatosis.

41 ularly among alcohol drinkers and those with hepatic steatosis.

42 2-/- mice are also resistant to diet-induced hepatic steatosis.

43 increased insulin sensitivity and decreased hepatic steatosis.

44 represents a novel mechanism of HCV-induced hepatic steatosis.

45 0.82; 95% CI: 0.68, 0.98; P = 0.02) but not hepatic steatosis.

46 ssion was also independently associated with hepatic steatosis.

47 pression of adiponectin, but did not prevent hepatic steatosis.

48 ed impairment of mitochondrial oxidation and hepatic steatosis.

49 abolic disorders, including dyslipidemia and hepatic steatosis.

50 iated with blood levels of liver enzymes and hepatic steatosis.

51 o completed liver ultrasound examination for hepatic steatosis.

52 sity, insulin resistance, hyperlipidemia and hepatic steatosis.

53 intestinal hypoxia-inducible factor (HIF) in hepatic steatosis.

54 nd fibrosis that are thought to emanate from hepatic steatosis.

55 her analyzed to evaluate their relation with hepatic steatosis.

56 sponse to feeding, exacerbating diet-induced hepatic steatosis.

57 ronger among alcohol drinkers and those with hepatic steatosis.

58 lop glucose intolerance and high fat-induced hepatic steatosis.

59 CI: 25, 49) were higher in participants with hepatic steatosis.

60 glucose homeostasis and prevents obesity and hepatic steatosis.

61 lipolysis and prevents high-fat diet-induced hepatic steatosis.

62 ein had significant shared gene effects with hepatic steatosis.

63 esses adipose tissue lipolysis, ameliorating hepatic steatosis.

64 Adult cnr2 mutants are susceptible to hepatic steatosis.

65 obesity-associated abnormalities, including hepatic steatosis.

66 tor finasteride induced hyperinsulinemia and hepatic steatosis (10.6 +/- 1.2 vs. 7.0 +/- 1.0 mumol g(

67 ights, HCLD feeding: (1) induced more severe hepatic steatosis; (2) up-regulated hepatic expression o

68 epatic steatosis than in adolescents without hepatic steatosis (41% compared with 18%; P = 0.04).

69 mice were protected against fasting-induced hepatic steatosis (a model of enhanced exogenous FA deli

70 Hepatic steatosis, a common finding in living liver dono

71 echanisms of inhalation exposure to PM2.5 on hepatic steatosis, a precursor or manifestation of metab

72 passes a range of conditions associated with hepatic steatosis, aberrant accumulation of fat in hepat

73 , HFD-fed AdSod2 KO mice were protected from hepatic steatosis, adipose tissue inflammation, and gluc

74 m the glucose intolerance, hyperinsulinemia, hepatic steatosis, adiposity, hypertension, myopathy, an

75 high-fat diet, as demonstrated by decreased hepatic steatosis, adiposity, plasmatic and hepatic trig

76 e proportion of patients without significant hepatic steatosis after 48 weeks was greater for those w

77 sociations between ambient air pollution and hepatic steatosis among 2,513 participants from the Fram

78 hing efavirenz (EFV) to raltegravir (RAL) on hepatic steatosis among HIV-infected patients with nonal

79 Dietary determinants of hepatic steatosis, an important precursor for nonalcohol

80 e Hedgehog pathway play an important role in hepatic steatosis and beyond.

81 esterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis.

82 roton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic steatosis in adu

83 ific 11beta-HSD1 KO mice were protected from hepatic steatosis and circulating fatty acid excess.

84 tions in obesity and type 2 diabetes include hepatic steatosis and disruption of glucose-glycogen hom

85 demonstrates that cellular senescence drives hepatic steatosis and elimination of senescent cells may

86 These improvements also lead to reduced hepatic steatosis and enhanced hepatic insulin sensitivi

87 udy examined the shared gene effects between hepatic steatosis and fibrosis and their associations wi

88 Studies have shown that hepatic steatosis and fibrosis are heritable, but whethe

89 Hepatic steatosis and fibrosis had a highly significant

90 bing exogenous hepatic FA use modulates both hepatic steatosis and fibrosis in the setting of hepatic

91 had transient elastography (TE) to evaluate hepatic steatosis and fibrosis.

92 d Fgf21 expression and reduced lipid-induced hepatic steatosis and glucose intolerance, but these eff

93 A study of twins provides evidence that hepatic steatosis and hepatic fibrosis are heritable tra

94 BH lysine 294 mutation in the liver leads to hepatic steatosis and hyperlipidemia in animals under pr

95 ced WAT lipolysis, glucocorticoid- initiated hepatic steatosis and hypertriglyceridemia were improved

96 de novo lipogenesis and prevent the onset of hepatic steatosis and hypertriglyceridemia.

97 FGF21 administration reduced alcohol-induced hepatic steatosis and inflammation in WT mice.

98 diet), CX3CR1 protected mice from excessive hepatic steatosis and inflammation, as well as systemic

99 improved insulin sensitivity, and decreased hepatic steatosis and inflammation.

100 rom peripheral lipolysis, showed exacerbated hepatic steatosis and inflammation.

101 ween diet, bile acids, sex, and dysbiosis in hepatic steatosis and inflammation.

102 ric HCLD feeding induced greater severity in hepatic steatosis and inflammatory response than HFLD fe

103 Hepatic steatosis and insulin resistance are among the m

104 t absorption and are protected from obesity, hepatic steatosis and insulin resistance associated with

105 es suggest that DPP-4 inhibition ameliorates hepatic steatosis and insulin resistance by suppressing

106 On high-fat diet, JAK2L mice had hepatic steatosis and insulin resistance despite protect

107 The development of hepatic steatosis and insulin resistance in CBA/J mice o

108 also efficacious in preventing and treating hepatic steatosis and insulin resistance induced by a hi

109 s an attractive target for the management of hepatic steatosis and insulin resistance.

110 0-mediated adipose tissue lipolysis promotes hepatic steatosis and insulin resistance.

111 or feeding them a high-fat diet, results in hepatic steatosis and insulin resistance.

112 in green coffee beans, prevents diet-induced hepatic steatosis and insulin resistance.

113 are protected against high-fat diet-induced hepatic steatosis and insulin resistance.

114 of SYK activation diminished alcohol-induced hepatic steatosis and interferon regulatory factor 3-med

115 ining 3 (PNPLA3) is robustly associated with hepatic steatosis and its progression to steatohepatitis

116 patic fatty acid esterification, ameliorates hepatic steatosis and lipid-induced insulin resistance.

117 Mice with high-fat diet-induced simple hepatic steatosis and lipid-loaded Huh7 cells had reduce

118 FGF21 depletion exacerbated alcohol-induced hepatic steatosis and liver injury, which was associated

119 terms of differences in insulin sensitivity, hepatic steatosis and metabolic outcomes in participants

120 BR may be a new therapeutic strategy against hepatic steatosis and non-alcoholic steatohepatitis.

121 nsumption have been implicated as a cause of hepatic steatosis and obesity but the effect of meal pat

122 ion of Hif2a, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower a

123 e Western diet, independently contributes to hepatic steatosis and obesity.

124 These changes were accompanied by reduced hepatic steatosis and oxidative stress in adipose tissue

125 The DPP-4 inhibitor prevented WD-induced hepatic steatosis and reduced hepatic insulin resistance

126 IO mice, which was linked to amelioration of hepatic steatosis and reduced inflammation in liver and

127 nd liver injury with significantly increased hepatic steatosis and serum AST level as well as hepatic

128 On chow, JAK2L mice had hepatic steatosis and severe whole-body and hepatic insu

129 om MCD formulas developed varying degrees of hepatic steatosis and steatohepatitis, in the order star

130 tivation of FGF21 by AHR contributed to both hepatic steatosis and systemic insulin hypersensitivity,

131 ion protects mice from high-fat diet-induced hepatic steatosis and that mutation of the SLC13A5 ortho

132 et (HFD) and high-carbohydrate diet (HCD) on hepatic steatosis and the underlying mechanisms, especia

133 Hepatic steatosis and VAT associated with significant ch

134 s of sugar and fat intake as determinants of hepatic steatosis and visceral obesity in overweight ado

135 duced adipose tissue inflammation as well as hepatic steatosis and was more effective at correcting h

136 Long-term GC treatment induces hepatic steatosis and weight gain.

137 ed hypertriglyceridemia, insulin resistance, hepatic steatosis, and diabetes.

138 posity, weight gain, hormonal dysregulation, hepatic steatosis, and dyslipidemia was reduced or rever

139 on against cardiac hypertrophy and fibrosis, hepatic steatosis, and gastrointestinal barrier dysfunct

140 , protection against diet-induced adiposity, hepatic steatosis, and glucose intolerance.

141 gen XVIII, developed reduced bulk-adiposity, hepatic steatosis, and hypertriglyceridemia.

142 FD-induced adipose and hepatic inflammation, hepatic steatosis, and insulin resistance.

143 yme, is increased in the livers of mice with hepatic steatosis, and knocking down Mogat1 improves glu

144 epr(db/db) HF mice developed marked obesity, hepatic steatosis, and more than 50% progressed to NASH

145 r's disease (AD), dermatological conditions, hepatic steatosis, and oncology.

146 and alanine aminotransferase concentrations; hepatic steatosis; and hepatic expression of IL-1alpha,

147 1 unit increase), diabetes (aOR: 1.56), and hepatic steatosis (aOR: 1.78) at the time of initial bio

148 sh that RBP4 expressed in adipocytes induces hepatic steatosis arising from primary effects occurring

149 ce were protected from high-fat diet-induced hepatic steatosis as well as from insulin resistance.

150 om insulin resistance, but are more prone to hepatic steatosis, as compared with their HFD-fed Ptpn6(

151 uctose-treated fish prevented development of hepatic steatosis, as did treatment of tunicamycin- or v

152 EFV to RAL showed decreases in the degree of hepatic steatosis, as measured by CAP, compared with tho

153 tly regulated and excessive lipolysis causes hepatic steatosis, as NEFA released from adipose tissue

154 BBR treatment also decreased hepatic steatosis, as well as the expression of acetyl-C

155 sults in reductions in circulating IGF-1 and hepatic steatosis, associated with systemic insulin resi

156 Changes in hepatic steatosis at 48 weeks of follow-up over baseline

157 between magnesium intake and alcohol use and hepatic steatosis at baseline were not significant (P >

158 NAFLD was defined as hepatic steatosis at nonenhanced CT (liver minus spleen

159 age, sex, and ethnicity, the heritability of hepatic steatosis (based on MRI-PDFF) was 0.52 (95% conf

160 ol (beta = -0.020; P = 7 x 10(-37)), greater hepatic steatosis (beta = 0.021; P = 3 x 10(-4)), higher

161 R of db/db mice reverted insulin resistance, hepatic steatosis, body weight and adiposity to those of

162 t promise for the quantitative assessment of hepatic steatosis but has not been validated in children

163 een reported to attenuate the development of hepatic steatosis, but the potential mechanisms remain p

164 ion of MED13 in mice conferred resistance to hepatic steatosis by activating a metabolic gene program

165 conclude that chronic inflammation precedes hepatic steatosis by disrupting the balance between fatt

166 report here that liver BVRA protects against hepatic steatosis by inhibiting glycogen synthase kinase

167 idly induces hepatic autophagy and abrogates hepatic steatosis by inhibiting hexose transport via the

168 Nrg4 gene transfer curbed HFD-induced hepatic steatosis by inhibiting lipogenesis and PPARgamm

169 activation play key roles in the response to hepatic steatosis by up-regulating apoA-IV and promoting

170 food allergies, type 1 and type 2 diabetes, hepatic steatosis, cardiovascular disease, and inflammat

171 & AIMS: Effective treatments are needed for hepatic steatosis characterized by accumulation of trigl

172 e had higher serum EtOH levels and developed hepatic steatosis characterized by micro- and macrovesic

173 density fat fraction (PDFF), a biomarker for hepatic steatosis, compared to histologic steatosis grad

174 e developed a multi-component classifier for hepatic steatosis comprised of phenotypic, genomic, and

175 agon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and

176 R1 deficiency induces insulin resistance and hepatic steatosis, consistent with the intrahepatic accu

177 bidities (for example, diabetes mellitus and hepatic steatosis) contribute to approximately 2.5 milli

178 The presence of hepatic steatosis correlated between monozygotic twins (

179 mination of liver samples from patients with hepatic steatosis demonstrated activation of Torc1 signa

180 mprovements in weight, glucose tolerance and hepatic steatosis despite differential effects on hepati

181 with chylomicron retention disorder develop hepatic steatosis, despite impaired intestinal fat malab

182 od why some, but not other, individuals with hepatic steatosis develop NASH.

183 Six weeks of WD feeding caused hepatic steatosis development as evidenced by the 2.25-f

184 , sub-chronic WD feeding appears to increase hepatic steatosis development over a 6-week period but o

185 C1 confers broad spectrum protection against hepatic steatosis development.

186 induced Zip14 KO mice show greater levels of hepatic steatosis due to higher expression of genes invo

187 CREBH-deficient mice developed severe hepatic steatosis due to increased adipose tissue lipoly

188 timulation contributes to the development of hepatic steatosis, dyslipidemia and hyperglycemia.

189 rodent diets with citrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance

190 ubsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin re

191 dividuals presented with a mild phenotype of hepatic steatosis, elevated aminotransferases and alkali

192 rogression of metabolic disorders, including hepatic steatosis, glucose intolerance, and inflammation

193 nction and ameliorates high-fat-diet-induced hepatic steatosis, glucose tolerance, and insulin resist

194 ex score >/=1.5, hepatic fibrosis >/=F3, and hepatic steatosis >/=S2 were independent factors associa

195 of hepatic fibrosis, and the heritability of hepatic steatosis has not been assessed systematically i

196 gnetic resonance imaging (MRI) biomarkers of hepatic steatosis have demonstrated tremendous promise f

197 aerobic capacity had no impact on WD-induced hepatic steatosis; however, rats bred for low aerobic ca

198 Hepatic steatosis (HS) is common in individuals with hep

199 We examined whether hepatic steatosis (HS) on ultrasound and liver enzyme ac

200 Primary endpoints were hepatic steatosis (HS; quantified by magnetic resonance

201 gain and associated comorbidities, including hepatic steatosis, hypercholesterolemia, and glucose int

202 uses obesity with visceral fat accumulation, hepatic steatosis, hyperleptinemia, hyperinsulinemia, an

203 ivation of Tm6sf2 in mice is associated with hepatic steatosis, hypocholesterolemia, and transaminiti

204 enuation parameter (CAP) in the diagnosis of hepatic steatosis in a series of overweight or obese chi

205 ) in grading hepatic steatosis and change in hepatic steatosis in adults with nonalcoholic steatohepa

206 de novo ceramide synthesis reduced PLIN2 and hepatic steatosis in alcohol-fed mice, but only de novo

207 improved lipid metabolism, and also reduced hepatic steatosis in diet-induced obese mice.

208 f obesity, insulin resistance, diabetes, and hepatic steatosis in diet-induced obese mice.

209 rately, forced PHLPP2 expression ameliorates hepatic steatosis in diet-induced obese mice.

210 Finally, E2f1 deletion completely abrogated hepatic steatosis in different murine models of nonalcoh

211 However, PM2.5 exposure relieved hepatic steatosis in high-fat diet-induced obese mice.

212 viral drugs with a lower potential to induce hepatic steatosis in human immunodeficiency virus (HIV)

213 We sought to determine the role of FGF21 in hepatic steatosis in mice exposed to chronic alcohol tre

214 NF6 in livers of adult C57Bl/6 mice leads to hepatic steatosis in mice fed normal laboratory chow.

215 ne, a natural compound that protects against hepatic steatosis in mice fed the high-fat diet, as a no

216 hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis in mice.

217 and genetic obesity, insulin resistance and hepatic steatosis in mice.

218 estigated mechanisms by which SIRT1 controls hepatic steatosis in mice.

219 SLC7A11 was associated with reduced risk of hepatic steatosis in participants (odds ratio, 0.69; 95%

220 ht gain, liver damage and the development of hepatic steatosis in prediabetic mice while protecting a

221 weight, enhance glycemic control and reverse hepatic steatosis in relevant rodent models.

222 sition in livers of control mice, but severe hepatic steatosis in SIRT1 LKO mice.

223 Both diets induced severe hepatic steatosis in the LTKO mice as compared to WT con

224 or diagnostic tests have been developed for hepatic steatosis in the setting of obesity.

225 ressed adipose tissue lipolysis and improved hepatic steatosis in these mice.

226 We investigated hepatic steatosis in transgenic mice expressing the HIV-

227 ed for treating the increasing prevalence of hepatic steatosis in Western populations.

228 ly, Crtc1 deficient mice develop spontaneous hepatic steatosis in young age.

229 several high-confidence candidate genes for hepatic steatosis, including Gde1, a glycerophosphodiest

230 f lipid dysregulation that can contribute to hepatic steatosis, including reduced triglyceride secret

231 on of 18:2 species with complete reversal of hepatic steatosis, increased hepatic injury, and worsene

232 hermore, ApoE-/-ITCH-/- mice exhibit reduced hepatic steatosis, increased mitochondrial oxidative cap

233 CD36Tg mice showed unexpected attenuation of hepatic steatosis, increased very low-density lipoprotei

234 s indexes (BMI), fatty liver index (FLI) and hepatic steatosis index (HSI) was analyzed using the imp

235 reduced obesity development and ameliorated hepatic steatosis induced by both high-fat diet treatmen

236 ation of pNaKtide reduced obesity as well as hepatic steatosis, inflammation and fibrosis.

237 enchyma as reflected in increased scores for hepatic steatosis, inflammation, fibrosis and NASH.

238 atic Ppargamma, i.e. C3H/HeN, do not develop hepatic steatosis, insulin resistance, or dysglycemia on

239 lic disorder characterized by lipodystrophy, hepatic steatosis, insulin resistance, severe diabetes,

240 host of diseases including atherosclerosis, hepatic steatosis, insulin resistance, type 2 diabetes,

241 ssociated fatty liver and insulin resistance.Hepatic steatosis is a common disease closely associated

242 Hepatic steatosis is a frequent complication associated

243 Hepatic steatosis is associated with a greater intake of

244 Hepatic steatosis is caused by metabolic imbalances that

245 Hepatic steatosis is characterised by excessive triglyce

246 Hepatic steatosis is common in obesity and insulin resis

247 Hepatic steatosis is defined by the accumulation of lipi

248 This indicates that hepatic steatosis is dissociated from insulin resistance

249 Hepatic steatosis is independent of androgens in rats.

250 of epigenetic changes in the development of hepatic steatosis is largely unknown.

251 bution of each hormone to the development of hepatic steatosis is unclear.

252 ssociated with markers of liver function and hepatic steatosis, laying the groundwork for future diag

253 9 +/- 103 vs. 313 +/- 66 ng mL(-1) min), and hepatic steatosis (liver triglycerides 136.1 +/- 17.0 vs

254 models and prevalence ratios for presence of hepatic steatosis (LPR </= 0.33) using generalized linea

255 Among the cohort, 20% (26/130) had hepatic steatosis (magnetic resonance imaging-proton den

256 Hepatic steatosis may be benign or progress to hepatocyt

257 n experimental animals and, while overcoming hepatic steatosis, may have significant gastrointestinal

258 nt rats including obesity, hyperinsulinemia, hepatic steatosis, nephropathy, and infertility.

259 t2 knockout mice are leaner and resistant to hepatic steatosis, obesity and insulin resistance under

260 eatment of dyslipidemia, insulin resistance, hepatic steatosis, obesity, and atherosclerosis.

261 represent an effective therapy for managing hepatic steatosis, obesity, and diabetes.

262 ge, which may be due to the manifestation of hepatic steatosis observed in the mice.

263 In the U.S. population, severe hepatic steatosis on ultrasound and liver enzyme elevati

264 ha-encoding gene Pik3r1 rescued diabetes and hepatic steatosis phenotypes of Kbtbd2(-/-) mice.

265 d catabolism, leads to AT atrophy and severe hepatic steatosis, phenotypes rescued by macrophage-spec

266 HFD also increased hepatic steatosis, plasma alanine aminotransferase activ

267 al: -0.006, -0.001) and higher prevalence of hepatic steatosis (prevalence ratio = 1.16, 95% confiden

268 nditions, n3-PUFA exert beneficial effect on hepatic steatosis, regeneration and inflammatory insults

269 Hepatic steatosis renders liver more vulnerable to ische

270 this study had a high prevalence of elevated hepatic steatosis scores.

271 Carriers of the mutation had dyslipidemia, hepatic steatosis, systemic insulin resistance, and diab

272 sumption was more common in adolescents with hepatic steatosis than in adolescents without hepatic st

273 f livers revealed that asparaginase provoked hepatic steatosis that coincided with activation of anot

274 IL-1-type cytokines can regulate hepatic steatosis; the NLR family pyrin domain containin

275 inal HIF-2alpha could be a viable target for hepatic steatosis therapy.

276 bile acid composition and in fasting-induced hepatic steatosis through a novel mechanism involving ac

277 multiple loci that confer susceptibility to hepatic steatosis through diverse metabolic mechanisms.

278 -expression of PNPLA8 dramatically decreases hepatic steatosis through increased autophagy in hepatoc

279 reveal a novel function of SRA in promoting hepatic steatosis through repression of ATGL expression.

280 lic fatty liver diseases (NAFLD) ranges from hepatic steatosis to steatohepatitis and fibrosis.

281 ggesting a possible specific contribution of hepatic steatosis to subclinical vascular impairment.

282 topathologic features, ranging from isolated hepatic steatosis, to steatohepatitis with evidence of h

283 Thus, PLD1 plays an important role in hepatic steatosis via the regulation of autophagy.

284 Similarly, SCFA-induced reduction of hepatic steatosis was absent in mice lacking hepatic PPA

285 Hepatic steatosis was assessed at baseline and after 72

286 Hepatic steatosis was assessed with magnetic resonance i

287 Hepatic steatosis was effectively reduced only in ob/ob

288 mice (Mttp-LKO, i.e., double knockout mice) hepatic steatosis was greatly diminished and fibrosis pr

289 t of PM2.5 exposure on high-fat diet-induced hepatic steatosis was mediated through PM2.5-induced hep

290 Hepatic steatosis was quantified noninvasively by MRI an

291 scular disease, patchy cardiac fibrosis, and hepatic steatosis, was noted in the other organs.

292 ory to weight gain, glucose intolerance, and hepatic steatosis when challenged with high-fat diet.

293 accurately classifies grades and changes in hepatic steatosis when histologic analysis of biopsies i

294 g and fasting blood glucose, weight gain and hepatic steatosis while protecting against diabetic neur

295 iated with gastrointestinal side effects and hepatic steatosis, whose long-term sequelae remain uncle

296 mass, fat content, glucose intolerance, and hepatic steatosis with advancing age.

297 cient mice fed a high fat diet had increased hepatic steatosis with significantly higher insulin resi

298 n patients with biopsy-proven NASH (n = 13), hepatic steatosis without NASH (n = 11), and healthy con

299 DNP improved glucose tolerance and reduced hepatic steatosis without observed toxicity.

300 triglyceride transfer protein (Mttp) causes hepatic steatosis, yet the risks for developing hepatic